

References

1. Damania, B. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. *Nat Rev Microbiol* **2**, 656-68 (2004).
2. Longnecker, R. & Neipel, F. Introduction to the human gamma-herpesviruses. in *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis* (eds. Arvin, A. *et al.*) (Cambridge, 2007).
3. Barton, E., Mandal, P. & Speck, S.H. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. *Annu Rev Immunol* **29**, 351-97 (2011).
4. Dalton-griffin, L. The role of host cell factors in the lytic reactivation of Kaposi ' s sarcoma-associated herpesvirus from latency. 1-279 (2010).
5. Epstein, M.A., Achong, B.G. & Barr, Y.M. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. *The Lancet* **283**, 702-703 (1964).
6. Burkitt, D. A sarcoma involving the jaws in African children. *Br J Surg* **46**, 218-23 (1958).
7. Henle, W., Diehl, V., Kohn, G., Zur Hausen, H. & Henle, G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. *Science* **157**, 1064-5 (1967).
8. Henle, G., Henle, W. & Diehl, V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. *Proc Natl Acad Sci U S A* **59**, 94-101 (1968).
9. zur Hausen, H. *et al.* EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. *Nature* **228**, 1056-8 (1970).
10. Ziegler, J.L. *et al.* Outbreak of Burkitt's-like lymphoma in homosexual men. *Lancet* **2**, 631-3 (1982).
11. Greenspan, J.S. *et al.* Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. *N Engl J Med* **313**, 1564-71 (1985).
12. Jones, J.F. *et al.* T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. *N Engl J Med* **318**, 733-41 (1988).
13. Weiss, L.M., Movahed, L.A., Warnke, R.A. & Sklar, J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. *N Engl J Med* **320**, 502-6 (1989).
14. Yao, Q.Y., Rickinson, A.B. & Epstein, M.A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. *Int J Cancer* **35**, 35-42 (1985).
15. Biggar, R.J. *et al.* Primary Epstein-Barr virus infections in African infants. I. Decline of maternal antibodies and time of infection. *Int J Cancer* **22**, 239-43 (1978).
16. de-The, G. Epstein-Barr virus behavior in different populations and implications for control of Epstein-Barr virus-associated tumors. *Cancer Res* **36**, 692-5 (1976).
17. Crawford, D.H. *et al.* A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis.

- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **43**, 276-82 (2006).
18. Mbulaiteye, S.M. *et al.* High levels of Epstein-Barr virus DNA in saliva and peripheral blood from Ugandan mother-child pairs. *The Journal of infectious diseases* **193**, 422-6 (2006).
 19. Hjalgrim, H., Friborg, J. & Melbye, M. The epidemiology of EBV and its association with malignant disease. in *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis* (eds. Arvin, A. *et al.*) (Cambridge, 2007).
 20. Daud, I.I. *et al.* Breast Milk as a Potential Source of Epstein-Barr Virus Transmission Among Infants Living in a Malaria-Endemic Region of Kenya. *The Journal of infectious diseases* **212**, 1735-42 (2015).
 21. Alfieri, C. *et al.* Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. *Blood* **87**, 812-7 (1996).
 22. Scheenstra, R. *et al.* The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. *Transpl Infect Dis* **6**, 15-22 (2004).
 23. Pagano, J.S. Is Epstein-Barr virus transmitted sexually? *J Infect Dis* **195**, 469-70 (2007).
 24. van Baarle, D. *et al.* High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission. *J Infect Dis* **181**, 2045-9 (2000).
 25. Chang, R.S., Rosen, L. & Kapikian, A.Z. Epstein-Barr virus infections in a nursery. *Am J Epidemiol* **113**, 22-9 (1981).
 26. Lang, D.J., Garruto, R.M. & Gajdusek, D.C. Early acquisition of cytomegalovirus and Epstein-Barr virus antibody in several isolated Melanesian populations. *Am J Epidemiol* **105**, 480-7 (1977).
 27. Dowd, J.B., Palermo, T., Brite, J., McDade, T.W. & Aiello, A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. *PLoS One* **8**, e64921 (2013).
 28. Sample, J. *et al.* Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. *J Virol* **64**, 4084-92 (1990).
 29. Gratama, J.W. & Ernberg, I. Molecular epidemiology of Epstein-Barr virus infection. *Adv Cancer Res* **67**, 197-255 (1995).
 30. Yao, Q.Y. *et al.* Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort. *J Virol* **72**, 4352-63 (1998).
 31. Cancian, L., Bosshard, R., Lucchesi, W., Karstegl, C.E. & Farrell, P.J. C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. *PLoS Pathog* **7**, e1002164 (2011).
 32. de Martel, C. *et al.* Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology* **13**, 607-615 (2012).

33. Group, I.W. *IARC monograph on the evaluation of carcinogenic risks to Humans. Volume 100b, Review of human carcinogens: biological agents. IARC, Lyon, France, 2011.*, 1-441 (2012).
34. Patsopoulos, N.A. *et al.* Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. *Ann Neurol* **70**, 897-912 (2011).
35. Ulf-Moller, C.J., Nielsen, N.M., Rostgaard, K., Hjalgrim, H. & Frisch, M. Epstein-Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosus. *Rheumatology (Oxford)* **49**, 1706-12 (2010).
36. Biggar, R.J. *et al.* Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. *Int J Cancer* **22**, 244-50 (1978).
37. Carpenter, L.M. *et al.* Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. *International journal of cancer* **122**, 1319-23 (2008).
38. Mutalima, N. *et al.* Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. *PLoS One* **3**, e2505 (2008).
39. Neel, H.B., 3rd, Pearson, G.R. & Taylor, W.F. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. *Ann Otol Rhinol Laryngol* **93**, 477-82 (1984).
40. Silins, S.L. *et al.* Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. *Blood* **98**, 3739-44 (2001).
41. Chang, R.S. & Chang, Y.Y. Activation of lymphocytes from Epstein-Barr virus-seronegative donors by autologous Epstein-Barr virus-transformed cells. *J Infect Dis* **142**, 156-62 (1980).
42. de-Thé, G. *et al.* Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. *Nature* **274**, 756-761 (1978).
43. Glaser, S.L. *et al.* Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. *Int J Cancer* **70**, 375-82 (1997).
44. Pallesen, G., Hamilton-Dutoit, S.J. & Zhou, X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. *Adv Cancer Res* **62**, 179-239 (1993).
45. Halprin, J. *et al.* Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma. *Ann Intern Med* **104**, 331-7 (1986).
46. Sam, C.K., Prasad, U. & Pathmanathan, R. Serological markers in the diagnosis of histopathological types of nasopharyngeal carcinoma. *Eur J Surg Oncol* **15**, 357-60 (1989).
47. Zeng, Y. *et al.* Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. *Int J Cancer* **29**, 139-41 (1982).
48. Baer, R. *et al.* DNA sequence and expression of the B95-8 Epstein-Barr virus genome. *Nature* **310**, 207-11 (1984).

49. Sixbey, J.W. *et al.* Replication of Epstein-Barr virus in human epithelial cells infected in vitro. *Nature* **306**, 480-3 (1983).
50. Allday, M.J. & Crawford, D.H. Role of epithelium in EBV persistence and pathogenesis of B-cell tumours. *Lancet* **1**, 855-7 (1988).
51. Anagnostopoulos, I., Hummel, M., Kreschel, C. & Stein, H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. *Blood* **85**, 744-50 (1995).
52. Niedobitek, G. *et al.* Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. *J Pathol* **182**, 151-9 (1997).
53. Fingeroth, J.D. *et al.* Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. *Proc Natl Acad Sci U S A* **81**, 4510-4 (1984).
54. Li, Q. *et al.* Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. *Journal of virology* **71**, 4657-62 (1997).
55. Kalla, M. & Hammerschmidt, W. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus. *Eur J Cell Biol* **91**, 65-9 (2012).
56. Babcock, G.J., Decker, L.L., Volk, M. & Thorley-Lawson, D.A. EBV persistence in memory B cells in vivo. *Immunity* **9**, 395-404 (1998).
57. Kieff, E. Epstein-Barr virus and its replication. in *Fields Virology. 3rd Ed., Vol. 2* (eds. Knipe, D.M. & Howley, P.M.) 2343-96 (Lippincott-Raven, Philadelphia, 1996).
58. Yates, J.L., Warren, N. & Sugden, B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. *Nature* **313**, 812-5 (1985).
59. Levitskaya, J. *et al.* Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. *Nature* **375**, 685-8 (1995).
60. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. *Proc Natl Acad Sci U S A* **94**, 12616-21 (1997).
61. Wilson, J.B., Bell, J.L. & Levine, A.J. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. *EMBO J* **15**, 3117-26 (1996).
62. Wilson, J.B. & Levine, A.J. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. *Curr Top Microbiol Immunol* **182**, 375-84 (1992).
63. Humme, S. *et al.* The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. *Proc Natl Acad Sci U S A* **100**, 10989-94 (2003).
64. Sheu, L.F. *et al.* Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo. *J Pathol* **180**, 243-8 (1996).
65. Ling, P.D., Hsieh, J.J., Ruf, I.K., Rawlins, D.R. & Hayward, S.D. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. *J Virol* **68**, 5375-83 (1994).

66. Grossman, S.R., Johannsen, E., Tong, X., Yalamanchili, R. & Kieff, E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. *Proc Natl Acad Sci U S A* **91**, 7568-72 (1994).
67. Kaiser, C. *et al.* The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. *J Virol* **73**, 4481-4 (1999).
68. Johannsen, E. *et al.* Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. *J Virol* **69**, 253-62 (1995).
69. Wang, F., Tsang, S.F., Kurilla, M.G., Cohen, J.I. & Kieff, E. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. *J Virol* **64**, 3407-16 (1990).
70. Wang, F. *et al.* Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. *J Virol* **64**, 2309-18 (1990).
71. Tomkinson, B., Robertson, E. & Kieff, E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. *J Virol* **67**, 2014-25 (1993).
72. Dawson, C.W., Rickinson, A.B. & Young, L.S. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. *Nature* **344**, 777-80 (1990).
73. Kaye, K.M., Izumi, K.M. & Kieff, E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. *Proc Natl Acad Sci U S A* **90**, 9150-4 (1993).
74. Gires, O. *et al.* Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. *EMBO J* **16**, 6131-40 (1997).
75. Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. *EMBO J* **17**, 1700-9 (1998).
76. Klein, E., Teramoto, N., Gogolak, P., Nagy, N. & Bjorkholm, M. LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. *Immunol Lett* **68**, 147-54 (1999).
77. Uchida, J. *et al.* Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. *Science* **286**, 300-3 (1999).
78. Eliopoulos, A.G., Blake, S.M., Floettmann, J.E., Rowe, M. & Young, L.S. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. *J Virol* **73**, 1023-35 (1999).
79. Eliopoulos, A.G. *et al.* TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. *J Virol* **77**, 1316-28 (2003).
80. Eliopoulos, A.G. & Young, L.S. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). *Oncogene* **16**, 1731-42 (1998).

81. Huen, D.S., Henderson, S.A., Croom-Carter, D. & Rowe, M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. *Oncogene* **10**, 549-60 (1995).
82. Kaye, K.M. *et al.* Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. *Proc Natl Acad Sci U S A* **93**, 11085-90 (1996).
83. Paine, E., Scheinman, R.I., Baldwin, A.S., Jr. & Raab-Traub, N. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. *J Virol* **69**, 4572-6 (1995).
84. Dawson, C.W., Tramontanis, G., Eliopoulos, A.G. & Young, L.S. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. *J Biol Chem* **278**, 3694-704 (2003).
85. Miller, C.L. *et al.* Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. *Immunity* **2**, 155-66 (1995).
86. Caldwell, R.G., Brown, R.C. & Longnecker, R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. *J Virol* **74**, 1101-13 (2000).
87. Caldwell, R.G., Wilson, J.B., Anderson, S.J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. *Immunity* **9**, 405-11 (1998).
88. Kang, M.S. & Kieff, E. Epstein-Barr virus latent genes. *Exp Mol Med* **47**, e131 (2015).
89. Tsurumi, T., Fujita, M. & Kudoh, A. Latent and lytic Epstein-Barr virus replication strategies. *Rev Med Virol* **15**, 3-15 (2005).
90. Mellinshoff, I. *et al.* Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. *Virology* **185**, 922-8 (1991).
91. Sinclair, A.J., Brimmell, M., Shanahan, F. & Farrell, P.J. Pathways of activation of the Epstein-Barr virus productive cycle. *J Virol* **65**, 2237-44 (1991).
92. Packham, G., Brimmell, M., Cook, D., Sinclair, A.J. & Farrell, P.J. Strain variation in Epstein-Barr virus immediate early genes. *Virology* **192**, 541-50 (1993).
93. Takada, K. & Ono, Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. *J Virol* **63**, 445-9 (1989).
94. Flemington, E. & Speck, S.H. Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos. *J Virol* **64**, 4549-52 (1990).
95. Flemington, E. & Speck, S.H. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. *J Virol* **64**, 1227-32 (1990).
96. Speck, S.H., Chatila, T. & Flemington, E. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. *Trends Microbiol* **5**, 399-405 (1997).

97. Lieberman, P.M. & Berk, A.J. In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. *J Virol* **64**, 2560-8 (1990).
98. Ragoczy, T., Heston, L. & Miller, G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. *J Virol* **72**, 7978-84 (1998).
99. Ragoczy, T. & Miller, G. Role of the Epstein-Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. *J Virol* **73**, 9858-66 (1999).
100. Murata, T. & Tsurumi, T. Switching of EBV cycles between latent and lytic states. *Rev Med Virol* **24**, 142-53 (2014).
101. Katsumura, K.R., Maruo, S. & Takada, K. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes. *J Med Virol* **84**, 504-10 (2012).
102. Kalla, M., Schmeinck, A., Bergbauer, M., Pich, D. & Hammerschmidt, W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. *Proc Natl Acad Sci U S A* **107**, 850-5 (2010).
103. Ma, S.D. *et al.* A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. *J Virol* **85**, 165-77 (2011).
104. Morrison, B.J., Labo, N., Miley, W.J. & Whitby, D. Serodiagnosis for tumor viruses. *Seminars in oncology* **42**, 191-206 (2015).
105. Evans, A.S., Wanat, J. & Niederman, J.C. Failure to demonstrate concomitant antibody changes to viral antigens other than Epstein-Barr virus (EBV) during or after infectious mononucleosis. *Yale J Biol Med* **56**, 203-9 (1983).
106. Coghill, A.E. & Hildesheim, A. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. *American journal of epidemiology* **180**, 687-95 (2014).
107. Cao, S.M. *et al.* Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. *PLoS One* **6**, e19100 (2011).
108. Hildesheim, A. & Wang, C.P. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors. *Semin Cancer Biol* **22**, 107-16 (2012).
109. Ji, M.F. *et al.* Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. *Br J Cancer* **96**, 623-30 (2007).
110. Yu, K.J. *et al.* Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. *Clin Cancer Res* **17**, 1906-14 (2011).
111. Chien, Y.C. *et al.* Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. *N Engl J Med* **345**, 1877-82 (2001).
112. Liu, Z. *et al.* Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster

- randomized controlled trial in Southern China. *Am J Epidemiol* **177**, 242-50 (2013).
113. Hildesheim, A. Invited commentary: Epstein-Barr virus-based screening for the early detection of nasopharyngeal carcinoma: a new frontier. *Am J Epidemiol* **177**, 251-3 (2013).
 114. Mueller, N. *et al.* Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. *The New England journal of medicine* **320**, 689-95 (1989).
 115. EVANS, A. PRESENCE OF ELEVATED ANTIBODY TITRES TO EPSTEIN-BARR VIRUS BEFORE HODGKIN'S DISEASE. *The Lancet* **317**, 1183-1186 (1981).
 116. Levin, L.I. *et al.* Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. *Blood* **120**, 3750-5 (2012).
 117. Mueller, N.E., Lennette, E.T., Dupnik, K. & Birmann, B.M. Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis. *Int J Cancer* **130**, 2886-91 (2012).
 118. Evans, A.S. & Gutensohn, N.M. A population-based case-control study of EBV and other viral antibodies among persons with Hodgkin's disease and their siblings. *Int J Cancer* **34**, 149-57 (1984).
 119. Geser, A., de Thé, G., Lenoir, G., Day, N.E. & Williams, E.H. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. *International journal of cancer* **29**, 397-400 (1982).
 120. Besson, C. *et al.* Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin's lymphoma patients and their relatives. *Journal of clinical microbiology* **44**, 47-50 (2006).
 121. Besson, C. *et al.* Strong correlations of anti-viral capsid antigen antibody levels in first-degree relatives from families with Epstein-Barr virus-related lymphomas. *The Journal of infectious diseases* **199**, 1121-7 (2009).
 122. Liu, M.T. & Yeh, C.Y. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). *Radiation medicine* **16**, 113-7.
 123. Nystad, T.W. & Myrmel, H. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* **38**, 292-7 (2007).
 124. Okano, M. *et al.* Frequent association of Epstein-Barr virus in Japanese patients with Burkitt's lymphoma. *Japanese journal of clinical oncology* **22**, 320-4 (1992).
 125. Orem, J. *et al.* Epstein-Barr virus viral load and serology in childhood non-Hodgkin's lymphoma and chronic inflammatory conditions in Uganda: implications for disease risk and characteristics. *Journal of medical virology* **86**, 1796-803 (2014).
 126. Piriou, E. *et al.* Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. *J Infect Dis* **205**, 906-13 (2012).
 127. Weinreb, M. *et al.* The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. *Blood* **87**, 3828-36 (1996).

128. Callan, M.F. The immune response to Epstein-Barr virus. *Microbes Infect* **6**, 937-45 (2004).
129. Landais, E., Saulquin, X. & Houssaint, E. The human T cell immune response to Epstein-Barr virus. *Int J Dev Biol* **49**, 285-92 (2005).
130. Pudney, V.A., Leese, A.M., Rickinson, A.B. & Hislop, A.D. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. *J Exp Med* **201**, 349-60 (2005).
131. Hislop, A.D. & Sabbah, S. CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus. *Semin Cancer Biol* **18**, 416-22 (2008).
132. Jayasooriya, S. *et al.* Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children. *PLoS Pathog* **11**, e1004746 (2015).
133. Long, H.M. *et al.* MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. *J Exp Med* **210**, 933-49 (2013).
134. Long, H.M. *et al.* CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. *J Virol* **79**, 4896-907 (2005).
135. Freeman, M.L. *et al.* Cutting edge: activation of virus-specific CD4 T cells throughout gamma-herpesvirus latency. *J Immunol* **187**, 6180-4 (2011).
136. Chang, Y. *et al.* Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* **266**, 1865-9 (1994).
137. Kaposi, M. Idiopathic Multiple Pigmented Sarcoma of the Skin. *CA: A Cancer Journal for Clinicians* **32**, 342-347 (1982).
138. Russo, J.J. *et al.* Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc Natl Acad Sci U S A* **93**, 14862-7 (1996).
139. Cesarman, E. & Mesri, E.A. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. *Curr Top Microbiol Immunol* **312**, 263-87 (2007).
140. Cesarman, E., Chang, Y., Moore, P.S., Said, J.W. & Knowles, D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N Engl J Med* **332**, 1186-91 (1995).
141. Uldrick, T.S. *et al.* An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. *Clin Infect Dis* **51**, 350-8 (2010).
142. Moore, P.S. & Chang, Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. *N Engl J Med* **332**, 1181-5 (1995).
143. Ferlay, J. *et al.* Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* **127**, 2893-917 (2010).
144. Hayward, G.S. KSHV strains: the origins and global spread of the virus. *Semin Cancer Biol* **9**, 187-99 (1999).
145. Mbulaiteye, S. *et al.* Molecular evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host. *J Infect Dis* **193**, 1250-7 (2006).

146. Mbulaiteye, S.M. *et al.* Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. *J Infect Dis* **190**, 1382-6 (2004).
147. Engels, E.A. *et al.* Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. *J Infect Dis* **196**, 199-207 (2007).
148. Martro, E. *et al.* Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. *Int J Cancer* **120**, 1129-35 (2007).
149. Chang, Y. *et al.* Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. *Arch Intern Med* **156**, 202-4 (1996).
150. Gao, S.J. *et al.* KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. *Nat Med* **2**, 925-8 (1996).
151. Chatlynne, L.G. & Ablashi, D.V. Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). *Semin Cancer Biol* **9**, 175-85 (1999).
152. Malope, B.I. *et al.* Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. *J Acquir Immune Defic Syndr* **44**, 351-5 (2007).
153. Mesri, E.A., Cesarman, E. & Boshoff, C. Kaposi's sarcoma and its associated herpesvirus. *Nat Rev Cancer* **10**, 707-19 (2010).
154. Butler, L.M. *et al.* Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. *J Infect Dis* **203**, 625-34 (2011).
155. Johnston, C. *et al.* Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. *PLoS One* **4**, e4222 (2009).
156. de-The, G., Bestetti, G., van Beveren, M. & Gessain, A. Prevalence of human herpesvirus 8 infection before the acquired immunodeficiency disease syndrome-related epidemic of Kaposi's sarcoma in East Africa. *J Natl Cancer Inst* **91**, 1888-9 (1999).
157. Dollard, S.C. *et al.* Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt". *Int J Cancer* **127**, 2395-401 (2010).
158. Gessain, A. *et al.* Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. *Int J Cancer* **81**, 189-92 (1999).
159. Rezza, G. *et al.* Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. *Sex Transm Dis* **27**, 159-64 (2000).
160. Engels, E.A. *et al.* Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. *Int J Cancer* **88**, 1003-8 (2000).
161. He, J. *et al.* Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. *J Infect Dis* **178**, 1787-90 (1998).

162. Olsen, S.J., Chang, Y., Moore, P.S., Biggar, R.J. & Melbye, M. Increasing Kaposi's sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. *AIDS* **12**, 1921-5 (1998).
163. Sitas, F. *et al.* Antibodies against human herpesvirus 8 in black South African patients with cancer. *N Engl J Med* **340**, 1863-71 (1999).
164. Cattani, P. *et al.* Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions. *Clin Microbiol Infect* **9**, 274-9 (2003).
165. Larocca, L. *et al.* Prevalence of antibodies to HHV-8 in the general population and in individuals at risk for sexually transmitted and blood-borne infections in Catania, Eastern Sicily. *Infez Med* **13**, 79-85 (2005).
166. Martin, J.N. *et al.* Sexual transmission and the natural history of human herpesvirus 8 infection. *N Engl J Med* **338**, 948-54 (1998).
167. Cao, Y. *et al.* High prevalence of early childhood infection by Kaposi's sarcoma-associated herpesvirus in a minority population in China. *Clin Microbiol Infect* **20**, 475-81 (2014).
168. Wang, H. *et al.* Seroprevalence and risk factors of Kaposi's sarcoma-associated herpesvirus infection among the general Uygur population from south and north region of Xinjiang, China. *Virology* **8**, 539 (2011).
169. de Souza, V.A. *et al.* Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region. *J Infect Dis* **196**, 844-52 (2007).
170. Mbulaiteye, S.M. *et al.* Human herpesvirus 8 infection within families in rural Tanzania. *J Infect Dis* **187**, 1780-5 (2003).
171. Plancoulaine, S. *et al.* Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. *Cancer Res* **64**, 8782-7 (2004).
172. Plancoulaine, S. *et al.* Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. *Lancet* **356**, 1062-5 (2000).
173. Alkharsah, K.R., Dedicoat, M., Blasczyk, R., Newton, R. & Schulz, T.F. Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. *J Infect Dis* **195**, 809-16 (2007).
174. Dedicoat, M. *et al.* Mother-to-child transmission of human herpesvirus-8 in South Africa. *J Infect Dis* **190**, 1068-75 (2004).
175. Olp, L.N. *et al.* Early childhood infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular analysis. *Int J Cancer* **132**, 1182-90 (2013).
176. Martro, E. *et al.* Comparison of human herpesvirus 8 and Epstein-Barr virus seropositivity among children in areas endemic and non-endemic for Kaposi's sarcoma. *Journal of medical virology* **72**, 126-31 (2004).
177. Crabtree, K.L. *et al.* Risk factors for early childhood infection of human herpesvirus-8 in Zambian children: the role of early childhood feeding practices. *Cancer Epidemiol Biomarkers Prev* **23**, 300-8 (2014).

178. Minhas, V. *et al.* Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. *Am J Epidemiol* **168**, 311-20 (2008).
179. Nalwoga, A. *et al.* Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. *Trop Med Int Health* **20**, 665-672 (2015).
180. Wakeham, K. *et al.* Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. *J Acquir Immune Defic Syndr* **63**, 228-33 (2013).
181. Wakeham, K. *et al.* Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. *Infect Agent Cancer* **6**, 15 (2011).
182. Whitby, D. *et al.* Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. *Int J Cancer* **120**, 321-8 (2007).
183. Lin, C.J. *et al.* Intestinal parasites in Kaposi sarcoma patients in Uganda: indication of shared risk factors or etiologic association. *Am J Trop Med Hyg* **78**, 409-12 (2008).
184. Ziegler, J.L. Endemic Kaposi's sarcoma in Africa and local volcanic soils. *Lancet* **342**, 1348-51 (1993).
185. Mbulaiteye, S.M. *et al.* Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers. *J Acquir Immune Defic Syndr* **38**, 474-9 (2005).
186. Zong, J.C. *et al.* High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. *J Virol* **73**, 4156-70 (1999).
187. Cook, P.M. *et al.* Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. *AIDS* **13**, 1165-76 (1999).
188. Brinkmann, M.M. & Schulz, T.F. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. *J Gen Virol* **87**, 1047-74 (2006).
189. Brinkmann, M.M., Pietrek, M., Dittrich-Breiholz, O., Kracht, M. & Schulz, T.F. Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. *J Virol* **81**, 42-58 (2007).
190. Brinkmann, M.M. *et al.* Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. *J Virol* **77**, 9346-58 (2003).
191. Choi, J.K., Lee, B.S., Shim, S.N., Li, M. & Jung, J.U. Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. *J Virol* **74**, 436-46 (2000).
192. Hayward, G.S. & Zong, J.C. Modern evolutionary history of the human KSHV genome. *Curr Top Microbiol Immunol* **312**, 1-42 (2007).

193. Beckstead, J.H., Wood, G.S. & Fletcher, V. Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. *Am J Pathol* **119**, 294-300 (1985).
194. Wang, H.W. *et al.* Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. *Nat Genet* **36**, 687-93 (2004).
195. Friedman-Kien, A.E. & Saltzman, B.R. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. *J Am Acad Dermatol* **22**, 1237-50 (1990).
196. Iscovich, J., Boffetta, P. & Brennan, P. Classic Kaposi's sarcoma as a first primary neoplasm. *Int J Cancer* **80**, 173-7 (1999).
197. Iscovich, J., Boffetta, P. & Brennan, P. Classic Kaposi's sarcoma in Arabs living in Israel, 1970-1993: a population-based incidence study. *Int J Cancer* **77**, 319-21 (1998).
198. Iscovich, J., Boffetta, P., Winkelmann, R., Brennan, P. & Azizi, E. Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. *AIDS* **12**, 2067-72 (1998).
199. Oettle, A.G. Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. *Acta Unio Int Contra Cancrum* **18**, 330-63 (1962).
200. Biggar, R.J. AIDS-related cancers in the era of highly active antiretroviral therapy. *Oncology (Williston Park)* **15**, 439-48; discussion 448-9 (2001).
201. Gaidano, G. & Carbone, A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. *Adv Cancer Res* **80**, 115-46 (2001).
202. Horenstein, M.G. *et al.* Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. *Blood* **90**, 1186-91 (1997).
203. Liang, C., Lee, J.S. & Jung, J.U. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. *Semin Cancer Biol* **18**, 423-36 (2008).
204. Jenner, R.G., Alba, M.M., Boshoff, C. & Kellam, P. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. *J Virol* **75**, 891-902 (2001).
205. Jenner, R.G. *et al.* Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. *Proc Natl Acad Sci U S A* **100**, 10399-404 (2003).
206. Soulier, J. *et al.* Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. *Blood* **86**, 1276-80 (1995).
207. Polizzotto, M.N. *et al.* Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. *Blood* **122**, 4189-98 (2013).
208. Larroche, C. *et al.* Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. *Am J Hematol* **69**, 119-26 (2002).
209. Chandran, B. Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells. *J Virol* **84**, 2188-99 (2010).

210. Bagni, R. & Whitby, D. Kaposi's sarcoma-associated herpesvirus transmission and primary infection. *Curr Opin HIV AIDS* **4**, 22-6 (2009).
211. Miller, G., El-Guindy, A., Countryman, J., Ye, J. & Gradoville, L. Lytic cycle switches of oncogenic human gammaherpesviruses. *Adv Cancer Res* **97**, 81-109 (2007).
212. Moore, P.S. & Chang, Y. Molecular virology of Kaposi's sarcoma-associated herpesvirus. *Philos Trans R Soc Lond B Biol Sci* **356**, 499-516 (2001).
213. Kellam, P. *et al.* Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. *J Hum Virol* **1**, 19-29 (1997).
214. Komatsu, T., Ballestas, M.E., Barbera, A.J. & Kaye, K.M. The KSHV latency-associated nuclear antigen: a multifunctional protein. *Front Biosci* **7**, d726-30 (2002).
215. Dittmer, D. *et al.* A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. *J Virol* **72**, 8309-15 (1998).
216. Kedes, D.H., Lagunoff, M., Renne, R. & Ganem, D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. *J Clin Invest* **100**, 2606-10 (1997).
217. Sadler, R. *et al.* A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. *J Virol* **73**, 5722-30 (1999).
218. Rainbow, L. *et al.* The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. *J Virol* **71**, 5915-21 (1997).
219. Verma, S.C., Lan, K. & Robertson, E. Structure and function of latency-associated nuclear antigen. *Curr Top Microbiol Immunol* **312**, 101-36 (2007).
220. Fejer, G. *et al.* The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts preferentially with the terminal repeats of the genome in vivo and this complex is sufficient for episomal DNA replication. *J Gen Virol* **84**, 1451-62 (2003).
221. Fakhari, F.D., Jeong, J.H., Kanan, Y. & Dittmer, D.P. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. *J Clin Invest* **116**, 735-42 (2006).
222. Friberg, J., Jr., Kong, W., Hottiger, M.O. & Nabel, G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. *Nature* **402**, 889-94 (1999).
223. Van Dross, R. *et al.* Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. *J Natl Cancer Inst* **97**, 656-66 (2005).
224. Direkze, S. & Laman, H. Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes. *Int J Exp Pathol* **85**, 305-19 (2004).
225. Sarek, G. *et al.* Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. *PLoS Pathog* **6**, e1000818 (2010).
226. Field, N. *et al.* KSHV vFLIP binds to IKK-gamma to activate IKK. *J Cell Sci* **116**, 3721-8 (2003).
227. Guasparri, I., Keller, S.A. & Cesarman, E. KSHV vFLIP is essential for the survival of infected lymphoma cells. *J Exp Med* **199**, 993-1003 (2004).

228. Liu, L. *et al.* The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the I κ B kinase complex. *J Biol Chem* **277**, 13745-51 (2002).
229. Ye, F.C. *et al.* Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF- κ B-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. *J Virol* **82**, 4235-49 (2008).
230. McCormick, C. & Ganem, D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. *Science* **307**, 739-41 (2005).
231. Purushothaman, P., Uppal, T. & Verma, S.C. Molecular biology of KSHV lytic reactivation. *Viruses* **7**, 116-53 (2015).
232. Sun, R. *et al.* Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. *J Virol* **73**, 2232-42 (1999).
233. Katano, H., Sato, Y., Itoh, H. & Sata, T. Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases. *J Hum Virol* **4**, 96-102 (2001).
234. Moore, P.S., Boshoff, C., Weiss, R.A. & Chang, Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. *Science* **274**, 1739-44 (1996).
235. Ganem, D. KSHV-induced oncogenesis. in *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis* (eds. Arvin, A. *et al.*) (Cambridge, 2007).
236. Lukac, D.M., Kirshner, J.R. & Ganem, D. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. *J Virol* **73**, 9348-61 (1999).
237. Yu, F. *et al.* B cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcoma-associated herpesvirus. *FEBS Lett* **581**, 3485-8 (2007).
238. Wilson, S.J. *et al.* X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. *J Virol* **81**, 13578-86 (2007).
239. Labo, N. *et al.* Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome. *PLoS Pathogens* **10**(2014).
240. Gao, S.J. *et al.* Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. *N Engl J Med* **335**, 233-41 (1996).
241. Ziegler, J. *et al.* Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. *Int J Cancer* **103**, 233-40 (2003).
242. Laney, A.S. *et al.* Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. *AIDS* **21**, 1541-5 (2007).
243. Wakeham, K. *et al.* Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. *Int J Cancer* **136**, 2822-30 (2015).
244. Robey, R.C., Mletzko, S. & Gotch, F.M. The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus. *Adv Virol* **2010**, 340356 (2010).

245. Hermans, P. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 15-year lessons from AIDS. *Biomed Pharmacother* **52**, 440-6 (1998).
246. Wang, Q.J. *et al.* Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. *Blood* **97**, 2366-73 (2001).
247. Guihot, A. *et al.* Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. *J Infect Dis* **194**, 1078-88 (2006).
248. Barozzi, P. *et al.* Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. *Transplantation* **86**, 738-44 (2008).
249. Lambert, M. *et al.* Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. *Blood* **108**, 3871-80 (2006).
250. Bourboulia, D. *et al.* Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. *AIDS* **18**, 485-93 (2004).
251. Strickler, H.D. *et al.* Human herpesvirus 8 cellular immune responses in homosexual men. *J Infect Dis* **180**, 1682-5 (1999).
252. Myoung, J. & Ganem, D. Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. *J Clin Invest* **121**, 1130-40 (2011).
253. Robey, R.C. *et al.* The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. *PLoS One* **4**, e5890 (2009).
254. Allison, A.C. Protection afforded by sickle-cell trait against subtertian malarial infection. *Br Med J* **1**, 290-4 (1954).
255. Comstock, G.W. Tuberculosis in twins: a re-analysis of the Proffit survey. *Am Rev Respir Dis* **117**, 621-4 (1978).
256. Herndon, C.N. & Jennings, R.G. A twin-family study of susceptibility to poliomyelitis. *Am J Hum Genet* **3**, 17-46 (1951).
257. Lin, T.M. *et al.* Hepatitis B virus markers in Chinese twins. *Anticancer Res* **9**, 737-41 (1989).
258. Misch, E.A., Berrington, W.R., Vary, J.C., Jr. & Hawn, T.R. Leprosy and the human genome. *Microbiol Mol Biol Rev* **74**, 589-620 (2010).
259. Sorensen, T.I., Nielsen, G.G., Andersen, P.K. & Teasdale, T.W. Genetic and environmental influences on premature death in adult adoptees. *N Engl J Med* **318**, 727-32 (1988).
260. Tournamille, C., Colin, Y., Cartron, J.P. & Le Van Kim, C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nat Genet* **10**, 224-8 (1995).
261. Samson, M. *et al.* Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* **382**, 722-5 (1996).

262. Newport, M.J. *et al.* A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. *N Engl J Med* **335**, 1941-9 (1996).
263. Dorman, S.E. & Holland, S.M. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. *J Clin Invest* **101**, 2364-9 (1998).
264. Altare, F. *et al.* Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. *J Clin Invest* **102**, 2035-40 (1998).
265. Everitt, A.R. *et al.* IFITM3 restricts the morbidity and mortality associated with influenza. *Nature* **484**, 519-23 (2012).
266. Zhang, Y.H. *et al.* Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. *Nat Commun* **4**, 1418 (2013).
267. International HapMap, C. The International HapMap Project. *Nature* **426**, 789-96 (2003).
268. Bush, W.S. & Moore, J.H. Chapter 11: Genome-wide association studies. *PLoS Comput Biol* **8**, e1002822 (2012).
269. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet* **44**, 955-9 (2012).
270. Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
271. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. *G3 (Bethesda)* **1**, 457-70 (2011).
272. Klein, R.J. *et al.* Complement factor H polymorphism in age-related macular degeneration. *Science* **308**, 385-9 (2005).
273. Jostins, L. *et al.* Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* **491**, 119-24 (2012).
274. Liu, J.Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979-86 (2015).
275. Replication, D.I.G. *et al.* Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet* **46**, 234-44 (2014).
276. Chapman, S.J. & Hill, A.V. Human genetic susceptibility to infectious disease. *Nat Rev Genet* **13**, 175-88 (2012).
277. Mentzer, A.J., O'Connor, D., Pollard, A.J. & Hill, A.V.S. Searching for the human genetic factors standing in the way of universally effective vaccines. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* **370**(2015).
278. Fellay, J. *et al.* A whole-genome association study of major determinants for host control of HIV-1. *Science* **317**, 944-7 (2007).
279. Fellay, J. *et al.* Common genetic variation and the control of HIV-1 in humans. *PLoS Genet* **5**, e1000791 (2009).

280. Pelak, K. *et al.* Host determinants of HIV-1 control in African Americans. *J Infect Dis* **201**, 1141-9 (2010).
281. International, H.I.V.C.S. *et al.* The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science* **330**, 1551-7 (2010).
282. Thomas, R. *et al.* HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. *Nat Genet* **41**, 1290-4 (2009).
283. Apps, R. *et al.* Influence of HLA-C expression level on HIV control. *Science* **340**, 87-91 (2013).
284. McLaren, P.J. *et al.* Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. *Proceedings of the National Academy of Sciences of the United States of America* (2015).
285. Hetherington, S. *et al.* Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet* **359**, 1121-2 (2002).
286. Mallal, S. *et al.* Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet* **359**, 727-32 (2002).
287. Kamatani, Y. *et al.* A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet* **41**, 591-5 (2009).
288. Matsuura, K., Isogawa, M. & Tanaka, Y. Host genetic variants influencing the clinical course of Hepatitis B virus infection. *Journal of medical virology* (2015).
289. Ge, D. *et al.* Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* **461**, 399-401 (2009).
290. Fitzmaurice, K. *et al.* Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. *Gut* **64**, 813-9 (2015).
291. Chen, D. *et al.* A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity. *Human molecular genetics* **24**, 2681-8 (2015).
292. Leish, G.E.N.C. *et al.* Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. *Nat Genet* **45**, 208-13 (2013).
293. Dunstan, S.J. *et al.* Variation at HLA-DRB1 is associated with resistance to enteric fever. *Nature genetics* **46**, 1333-6 (2014).
294. Sveinbjornsson, G. *et al.* HLA class II sequence variants influence tuberculosis risk in populations of European ancestry. *Nature genetics* **48**, 318-322 (2016).
295. Blackwell, J.M., Jamieson, S.E. & Burgner, D. HLA and infectious diseases. *Clin Microbiol Rev* **22**, 370-85, Table of Contents (2009).
296. Burdett T (EBI), H.P.N., Hastings E (EBI), Hindorff LA (NHGRI), Junkins HA (NHGRI), Klemm AK (NHGRI), MacArthur J (EBI), Manolio TA (NHGRI), Morales J (EBI), Parkinson H (EBI) and Welter D (EBI). The NHGRI-EBI Catalog of published genome-wide association studies. Available at: <http://www.ebi.ac.uk/gwas> Accessed: 12/04/2016.

297. Peprah, E., Xu, H., Tekola-Ayele, F. & Royal, C.D. Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease. *Public health genomics* **18**, 40-51 (2015).
298. Campbell, M.C. & Tishkoff, S.A. The evolution of human genetic and phenotypic variation in Africa. *Curr Biol* **20**, R166-73 (2010).
299. Gurdasani, D. *et al.* The African Genome Variation Project shapes medical genetics in Africa. *Nature advance on*(2014).
300. Jallow, M. *et al.* Genome-wide and fine-resolution association analysis of malaria in West Africa. *Nat Genet* **41**, 657-65 (2009).
301. Band, G. *et al.* Imputation-based meta-analysis of severe malaria in three African populations. *PLoS Genet* **9**, e1003509 (2013).
302. Kenyan Bacteraemia Study, G. *et al.* Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. *Am J Hum Genet* **98**, 1092-100 (2016).
303. Spencer, C.C., Su, Z., Donnelly, P. & Marchini, J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. *PLoS Genet* **5**, e1000477 (2009).
304. Rotimi, C. *et al.* Research capacity. Enabling the genomic revolution in Africa. *Science (New York, N.Y.)* **344**, 1346-8 (2014).
305. De Flora, S. & La Maestra, S. Epidemiology of cancers of infectious origin and prevention strategies. *Journal of preventive medicine and hygiene* **56**, E15-20 (2015).
306. Jemal, A. *et al.* Cancer burden in Africa and opportunities for prevention. *Cancer* **118**, 4372-84 (2012).
307. Khan, G. & Hashim, M.J. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. *Infect Agent Cancer* **9**, 38 (2014).
308. Bouvard, V. *et al.* A review of human carcinogens--Part B: biological agents. *Lancet Oncol* **10**, 321-2 (2009).
309. Brown, E.E. *et al.* Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma. *Int J Epidemiol* **34**, 1110-7 (2005).
310. Pelsler, C. *et al.* Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily. *J Med Virol* **81**, 1938-44 (2009).
311. Vitale, F. *et al.* Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. *Int J Cancer* **91**, 588-91 (2001).
312. Engels, E.a. *et al.* Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. *The Journal of infectious diseases* **196**, 199-207 (2007).
313. Aoki, Y. & Tosato, G. Interactions between HIV-1 Tat and KSHV. *Curr Top Microbiol Immunol* **312**, 309-26 (2007).
314. Boshoff, C., Whitby, D., Talbot, S. & Weiss, R.A. Etiology of AIDS-related Kaposi's sarcoma and lymphoma. *Oral Dis* **3 Suppl 1**, S129-32 (1997).

315. Merat, R. *et al.* HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. *Int J Cancer* **97**, 791-5 (2002).
316. Whitby, D. *et al.* Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. *Lancet* **346**, 799-802 (1995).
317. Bhutani, M., Polizzotto, M.N., Uldrick, T.S. & Yarchoan, R. Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. *Semin Oncol* **42**, 223-46 (2015).
318. Newton, R. *et al.* Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda. *British journal of cancer* **89**, 502-504 (2003).
319. Rohner, E. *et al.* HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis. *Int J Cancer* **138**, 45-54 (2016).
320. Ariyoshi, K. *et al.* Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. *J Hum Virol* **1**, 193-9 (1998).
321. Pinzone, M.R., Berretta, M., Cacopardo, B. & Nunnari, G. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. *Seminars in oncology* **42**, 258-71 (2015).
322. Engels, E.A. *et al.* Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer* **123**, 187-94 (2008).
323. Krause, J.R., Robinson, S.D. & Vance, E.A. Multicentric Castleman's disease and HIV. *Proc (Bayl Univ Med Cent)* **27**, 28-30 (2014).
324. Powles, T. *et al.* The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. *Ann Oncol* **20**, 775-9 (2009).
325. Okada, S., Goto, H. & Yotsumoto, M. Current status of treatment for primary effusion lymphoma. *Intractable Rare Dis Res* **3**, 65-74 (2014).
326. Suda, T. *et al.* HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. *Pathol Int* **51**, 671-9 (2001).
327. Greene, W. *et al.* Molecular biology of KSHV in relation to AIDS-associated oncogenesis. *Cancer Treat Res* **133**, 69-127 (2007).
328. Mercader, M. *et al.* Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. *Am J Pathol* **156**, 1961-71 (2000).
329. Varthakavi, V., Smith, R.M., Deng, H., Sun, R. & Spearman, P. Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. *Virology* **297**, 270-80 (2002).

330. Mbulaiteye, S.M., Biggar, R.J., Goedert, J.J. & Engels, E.A. Immune deficiency and risk for malignancy among persons with AIDS. *J Acquir Immune Defic Syndr* **32**, 527-33 (2003).
331. Zeng, Y. *et al.* Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling. *J Virol* **81**, 2401-17 (2007).
332. Biggar, R.J., Chaturvedi, A.K., Goedert, J.J., Engels, E.A. & Study, H.A.C.M. AIDS-related cancer and severity of immunosuppression in persons with AIDS. *J Natl Cancer Inst* **99**, 962-72 (2007).
333. Gallo, R.C. The enigmas of Kaposi's sarcoma. *Science* **282**, 1837-9 (1998).
334. Douglas, J.L., Gustin, J.K., Moses, A.V., Dezube, B.J. & Pantanowitz, L. Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation. *Transl Biomed* **1**(2010).
335. Huang, L.M. *et al.* Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. *J Biol Chem* **276**, 13427-32 (2001).
336. Caselli, E. *et al.* Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. *Blood* **106**, 2790-7 (2005).
337. Caselli, E., Galvan, M., Cassai, E. & Di Luca, D. Transient expression of human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 enhances HIV-1 replication. *Intervirology* **46**, 141-9 (2003).
338. Caselli, E. *et al.* Human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. *J Gen Virol* **82**, 1965-70 (2001).
339. Hyun, T.S., Subramanian, C., Cotter, M.A., 2nd, Thomas, R.A. & Robertson, E.S. Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. *J Virol* **75**, 8761-71 (2001).
340. Karijolich, J., Zhao, Y., Peterson, B., Zhou, Q. & Glaunsinger, B. Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2. *J Virol* **88**, 7024-35 (2014).
341. Carbone, A., Cesarman, E., Spina, M., Gloghini, A. & Schulz, T.F. HIV-associated lymphomas and gamma-herpesviruses. *Blood* **113**, 1213-24 (2009).
342. Carbone, A. & Gloghini, A. AIDS-related lymphomas: from pathogenesis to pathology. *Br J Haematol* **130**, 662-70 (2005).
343. Pietersma, F., Piriou, E. & van Baarle, D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. *Leuk Lymphoma* **49**, 1028-41 (2008).
344. Wabinga, H.R., Parkin, D.M., Wabwire-Mangen, F. & Mugerwa, J.W. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. *Int J Cancer* **54**, 26-36 (1993).
345. Grogg, K.L., Miller, R.F. & Dogan, A. HIV infection and lymphoma. *J Clin Pathol* **60**, 1365-72 (2007).

346. Biggar, R.J. *et al.* Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. *Blood* **108**, 3786-91 (2006).
347. Bibas, M. & Antinori, A. EBV and HIV-Related Lymphoma. *Mediterr J Hematol Infect Dis* **1**, e2009032 (2009).
348. Orem, J., Maganda, A., Mbidde, E.K. & Weiderpass, E. Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection. *Pediatric blood & cancer* **52**, 455-8 (2009).
349. Carbone, A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. *Hum Pathol* **33**, 392-404 (2002).
350. Beral, V., Peterman, T., Berkelman, R. & Jaffe, H. AIDS-associated non-Hodgkin lymphoma. *Lancet* **337**, 805-9 (1991).
351. Ziegler, J.L. *et al.* Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. *N Engl J Med* **311**, 565-70 (1984).
352. Polesel, J. *et al.* Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS* **22**, 301-6 (2008).
353. Cote, T.R. *et al.* Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. *Int J Cancer* **73**, 645-50 (1997).
354. Diamond, C., Taylor, T.H., Aboumrad, T. & Anton-Culver, H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. *Cancer* **106**, 128-35 (2006).
355. Orem, J., Otieno, M.W. & Remick, S.C. AIDS-associated cancer in developing nations. *Curr Opin Oncol* **16**, 468-76 (2004).
356. Rohner, E. *et al.* HHV-8 seroprevalence: a global view. *Syst Rev* **3**, 11 (2014).
357. Coghill, A.E. *et al.* Contribution of HIV infection to mortality among cancer patients in Uganda. *AIDS* **27**, 2933-42 (2013).
358. Trivedi, P. *et al.* Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. *Blood* **103**, 313-6 (2004).
359. Boshoff, C. *et al.* Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. *Blood* **91**, 1671-9 (1998).
360. Krithivas, A., Young, D.B., Liao, G., Greene, D. & Hayward, S.D. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. *J Virol* **74**, 9637-45 (2000).
361. Xu, D. *et al.* Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. *J Virol* **81**, 6068-78 (2007).
362. Jiang, Y., Xu, D., Zhao, Y. & Zhang, L. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. *PLoS One* **3**, e1569 (2008).

363. Spadavecchia, S., Gonzalez-Lopez, O., Carroll, K.D., Palmeri, D. & Lukac, D.M. Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfecting cells. *J Virol* **84**, 10488-500 (2010).
364. Kempkes, B. & Robertson, E.S. Epstein-Barr virus latency: current and future perspectives. *Current opinion in virology* **14**, 138-44 (2015).
365. Mbulaiteye, S.M. Burkitt Lymphoma: beyond discoveries. *Infect Agent Cancer* **8**, 35 (2013).
366. Morrow, R.H. Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt's lymphoma. *IARC scientific publications*, 177-86 (1985).
367. Njie, R. *et al.* The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. *The Journal of infectious diseases* **199**, 31-8 (2009).
368. Orem, J., Mbidde, E.K., Lambert, B., de Sanjose, S. & Weiderpass, E. Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. *African health sciences* **7**, 166-75 (2007).
369. Piriou, E. *et al.* Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. *J Med Virol* **81**, 1088-93 (2009).
370. Conant, K.L., Marinelli, A. & Kaleeba, J.A. Dangerous liaisons: molecular basis for a syndemic relationship between Kaposi's sarcoma and *P. falciparum* malaria. *Front Microbiol* **4**, 35 (2013).
371. Beltra, J.-C. & Decaluwe, H. Cytokines and persistent viral infections. *Cytokine* (2016).
372. Chang, K.C. *et al.* Pathogenesis of virus-associated human cancers: Epstein-Barr virus and hepatitis B virus as two examples. *J Formos Med Assoc* **113**, 581-90 (2014).
373. Mbulaiteye, S.M. *et al.* Seroprevalence and risk factors for human herpesvirus 8 infection, rural Egypt. *Emerg Infect Dis* **14**, 586-91 (2008).
374. Mbulaiteye, S.M. *et al.* Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study. *J Clin Virol* **35**, 442-9 (2006).
375. Kamali, A. *et al.* Seven-year trends in HIV-1 infection rates, and changes in sexual behaviour, among adults in rural Uganda. *AIDS* **14**, 427-34 (2000).
376. KENGEYA-KAYONDO, J.-F. *et al.* Incidence of HIV-1 Infection in Adults and Socio-Demographic Characteristics of Seroconverters in a Rural Population in Uganda: 1990–1994. *International Journal of Epidemiology* **25**, 1077-1082 (1996).
377. Nalwoga, A. *et al.* Nutritional status of children living in a community with high HIV prevalence in rural Uganda: a cross-sectional population-based survey. *Tropical medicine & international health : TM & IH* **15**, 414-22 (2010).
378. Pfeiffer, R.M. *et al.* Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. *Ann Epidemiol* **20**, 958-63 (2010).
379. Emmanuel, B. *et al.* African Burkitt lymphoma: age-specific risk and correlations with malaria biomarkers. *Am J Trop Med Hyg* **84**, 397-401 (2011).

380. Biggar, R.J. AIDS in subsaharan Africa. *Cancer Detect Prev Suppl* **1**, 487-91 (1987).
381. Biryahwaho, B. *et al.* Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. *J Infect Dis* **202**, 1347-53 (2010).
382. Butler, L.M. *et al.* Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. *J Infect Dis* **200**, 430-8 (2009).
383. Kalungi, S., Wabinga, H. & Bostad, L. Reactive lymphadenopathy in Ugandan patients and its relationship to EBV and HIV infection. *APMIS* **117**, 302-7 (2009).
384. Mbulaiteye, S.M. *et al.* Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. *Int J Cancer* **118**, 985-90 (2006).
385. Newton, R. *et al.* The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. *International journal of cancer. Journal international du cancer* **103**, 226-32 (2003).
386. Ogwang, M.D., Bhatia, K., Biggar, R.J. & Mbulaiteye, S.M. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. *Int J Cancer* **123**, 2658-63 (2008).
387. Parkin, D.M., Namboozee, S., Wabwire-Mangen, F. & Wabinga, H.R. Changing cancer incidence in Kampala, Uganda, 1991-2006. *Int J Cancer* **126**, 1187-95 (2010).
388. Nunn, A.J. *et al.* Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study. *BMJ* **315**, 767-771 (1997).
389. Asiki, G. *et al.* The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. *Int J Epidemiol* **42**, 129-41 (2013).
390. Mbulaiteye, S.M., Mahe, C., Ruberantwari, A. & Whitworth, J.A. Generalizability of population-based studies on AIDS: a comparison of newly and continuously surveyed villages in rural southwest Uganda. *Int J Epidemiol* **31**, 961-7 (2002).
391. Richards, A.I. *Economic development and tribal change : a study of immigrant labour in Buganda*, xix, 319 p., 8 leaves of plates (Oxford University Press, Nairobi, 1973).
392. Binnicker, M.J., Jespersen, D.J., Harring, J.A., Rollins, L.O. & Beito, E.M. Evaluation of a multiplex flow immunoassay for detection of epstein-barr virus-specific antibodies. *Clin Vaccine Immunol* **15**, 1410-3 (2008).
393. Mbisa, G.L. *et al.* Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: A new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. *Journal of Immunological Methods* **356**, 39-46 (2010).
394. Krajden, M. Hepatitis C virus diagnosis and testing. *Can J Public Health* **91 Suppl 1**, S34-9, S36-42 (2000).
395. Krajden, M., McNabb, G. & Petric, M. The laboratory diagnosis of hepatitis B virus. *Can J Infect Dis Med Microbiol* **16**, 65-72 (2005).
396. Quesada, P. *et al.* Hepatitis C virus seroprevalence in the general female population from 8 countries. *J Clin Virol* **68**, 89-93 (2015).

397. R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0.
398. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-75 (2007).
399. Price, A.L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nature genetics* **38**, 904-9 (2006).
400. Heckerman, D. *et al.* Linear mixed model for heritability estimation that explicitly addresses environmental variation. *Proceedings of the National Academy of Sciences* **113**, 7377-7382 (2016).
401. O'Connell, J. *et al.* A general approach for haplotype phasing across the full spectrum of relatedness. *PLoS genetics* **10**, e1004234 (2014).
402. O'Connell, J. *et al.* A general approach for haplotype phasing across the full spectrum of relatedness. *PLoS Genet* **10**, e1004234 (2014).
403. Visscher, P.M. *et al.* Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings. *PLoS Genet* **2**, e41 (2006).
404. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat Genet* **42**, 565-9 (2010).
405. Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G. & Ott, J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* **386**, 1546-55 (2015).
406. Karoney, M.J. & Siika, A.M. Hepatitis C virus (HCV) infection in Africa: a review. *Pan Afr Med J* **14**, 44 (2013).
407. Shebl, F.M. *et al.* Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans. *J Med Virol* **85**, 1602-10 (2013).
408. Zeng, P. *et al.* Statistical analysis for genome-wide association study. *J Biomed Res* **29**, 285-97 (2015).
409. Chen, C.J. *et al.* Genetic variance and heritability of temperament among Chinese twin infants. *Acta Genet Med Gemellol (Roma)* **39**, 485-90 (1990).
410. Zaitlen, N. *et al.* Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits. *PLoS Genet* **9**, e1003520 (2013).
411. Rubicz, R. *et al.* Genetic factors influence serological measures of common infections. *Hum Hered* **72**, 133-41 (2011).
412. Rubicz, R. *et al.* A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1). *PLoS Genet* **9**, e1003147 (2013).
413. Zhou, Y. *et al.* Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)* (2016).
414. Rubicz, R. *et al.* Genome-wide genetic investigation of serological measures of common infections. *Eur J Hum Genet* **23**, 1544-8 (2015).
415. Bei, J.X., Jia, W.H. & Zeng, Y.X. Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. *Semin Cancer Biol* **22**, 96-106 (2012).

416. Hjalgrim, H. *et al.* Familial clustering of Hodgkin lymphoma and multiple sclerosis. *J Natl Cancer Inst* **96**, 780-4 (2004).
417. Houldcroft, C.J. & Kellam, P. Host genetics of Epstein-Barr virus infection, latency and disease. *Rev Med Virol* **25**, 71-84 (2015).
418. Hurme, M. & Helminen, M. Polymorphism of the IL-1 gene complex in Epstein-Barr virus seronegative and seropositive adult blood donors. *Scand J Immunol* **48**, 219-22 (1998).
419. Hatta, K. *et al.* Association of transforming growth factor-beta1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases. *Haematologica* **92**, 1470-4 (2007).
420. Suthanthiran, M. *et al.* Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. *Proc Natl Acad Sci U S A* **97**, 3479-84 (2000).
421. Yamada, Y. *et al.* Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. *J Bone Miner Res* **13**, 1569-76 (1998).
422. Blomhoff, H.K., Smeland, E., Mustafa, A.S., Godal, T. & Ohlsson, R. Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage. *Eur J Immunol* **17**, 299-301 (1987).
423. Helminen, M., Lahdenpohja, N. & Hurme, M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. *The Journal of infectious diseases* **180**, 496-9 (1999).
424. Helminen, M.E., Kilpinen, S., Virta, M. & Hurme, M. Susceptibility to primary Epstein-Barr virus infection is associated with interleukin-10 gene promoter polymorphism. *The Journal of infectious diseases* **184**, 777-80 (2001).
425. Minnicelli, C. *et al.* Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. *PLoS One* **7**, e46005 (2012).
426. Yasui, Y. *et al.* Association of Epstein-Barr virus antibody titers with a human IL-10 promoter polymorphism in Japanese women. *Journal of autoimmune diseases* **5**, 2 (2008).
427. Munro, L.R. *et al.* Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. *Leuk Lymphoma* **44**, 2083-8 (2003).
428. Wu, M.S. *et al.* Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. *Int J Cancer* **104**, 617-23 (2003).
429. Oduor, C.I. *et al.* Interleukin-6 and interleukin-10 gene promoter polymorphisms and risk of endemic Burkitt lymphoma. *Am J Trop Med Hyg* **91**, 649-54 (2014).
430. Durovic, B. *et al.* Epstein-Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy. *J Virol* **87**, 6526-9 (2013).
431. Diepstra, A. *et al.* Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. *Lancet* **365**, 2216-24 (2005).

432. Niens, M. *et al.* The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. *Cancer Epidemiol Biomarkers Prev* **15**, 2280-4 (2006).
433. Niens, M. *et al.* HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. *Blood* **110**, 3310-5 (2007).
434. Hjalgrim, H. *et al.* HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. *Proc Natl Acad Sci U S A* **107**, 6400-5 (2010).
435. McAulay, K.A. *et al.* HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. *The Journal of clinical investigation* **117**, 3042-8 (2007).
436. Claire Simon, K., Schmidt, H., Loud, S. & Ascherio, A. Epstein-Barr virus candidate genes and multiple sclerosis. *Multiple sclerosis and related disorders* **4**, 60-4 (2015).
437. Nielsen, T.R., Pedersen, M., Rostgaard, K., Frisch, M. & Hjalgrim, H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. *Mult Scler* **13**, 420-3 (2007).
438. Huang, X. *et al.* HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. *PLoS One* **7**, e31865 (2012).
439. Huang, X. *et al.* HLA associations in classical Hodgkin lymphoma: EBV status matters. *PLoS One* **7**, e39986 (2012).
440. Johnson, P.C.D. *et al.* Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis. *International journal of cancer. Journal international du cancer* (2015).
441. Friborg, J.T. *et al.* Mannose-binding lectin genotypes and susceptibility to Epstein-Barr virus infection in infancy. *Clin Vaccine Immunol* **17**, 1484-7 (2010).
442. Shen, G.-P. *et al.* Human genetic variants of homologous recombination repair genes first found to be associated with Epstein-Barr virus antibody titers in healthy Cantonese. *International journal of cancer. Journal international du cancer* **129**, 1459-66 (2011).
443. Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* **42**, D1001-6 (2014).
444. Pedergnana, V. *et al.* Combined linkage and association studies show that HLA class II variants control levels of antibodies against Epstein-Barr virus antigens. *PLoS One* **9**, e102501 (2014).
445. Hammer, C. *et al.* Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of Humoral Response to Common Viruses. *Am J Hum Genet* **97**, 738-43 (2015).
446. Houldcroft, C.J. *et al.* Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines. *PLoS One* **9**, e108384 (2014).

447. Urayama, K.Y. *et al.* Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. *J Natl Cancer Inst* **104**, 240-53 (2012).
448. Tang, M. *et al.* The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. *PLoS Genet* **8**, e1003103 (2012).
449. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS genetics* **5**, e1000529 (2009).
450. Zhou, X. & Stephens, M. Efficient multivariate linear mixed model algorithms for genome-wide association studies. *Nature methods* **11**, 407-9 (2014).
451. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nature genetics* **44**, 369-75, S1-3 (2012).
452. Morris, A.P. Transethnic meta-analysis of genomewide association studies. *Genetic epidemiology* **35**, 809-22 (2011).
453. Hammer, C. *et al.* Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of Humoral Response to Common Viruses. *American journal of human genetics* (2015).
454. Wang, X. *et al.* Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies. *Human molecular genetics* **22**, 2303-11 (2013).
455. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
456. Charles, B.A. *et al.* A genome-wide association study of serum uric acid in African Americans. *BMC Med Genomics* **4**, 17 (2011).
457. Maller, J.B. *et al.* Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nature genetics* **44**, 1294-301 (2012).
458. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).
459. Zhou, X. & Stephens, M. Efficient multivariate linear mixed model algorithms for genome-wide association studies. *Nat Methods* **11**, 407-9 (2014).
460. Rippe, V. *et al.* Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. *Oncogene* **22**, 6111-4 (2003).
461. Hatton, O.L., Harris-Arnold, A., Schaffert, S., Krams, S.M. & Martinez, O.M. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. *Immunol Res* **58**, 268-76 (2014).
462. Snow, A.L. *et al.* Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. *J Immunol* **167**, 5404-11 (2001).
463. Snow, A.L. *et al.* EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. *J Immunol* **177**, 3283-93 (2006).
464. Zeggini, E. *et al.* Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat Genet* **40**, 638-45 (2008).

465. Chen, Z.J. *et al.* Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. *Nat Genet* **43**, 55-9 (2011).
466. Franke, A. *et al.* Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* **42**, 1118-25 (2010).
467. Eeles, R.A. *et al.* Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. *Nat Genet* **41**, 1116-21 (2009).
468. Zhao, Y. *et al.* GALC gene is downregulated by promoter hypermethylation in Epstein-Barr virus-associated nasopharyngeal carcinoma. *Oncology Reports* **34**, 1369-1378 (2015).
469. Chu, P.J., Robertson, H.M. & Best, P.M. Calcium channel gamma subunits provide insights into the evolution of this gene family. *Gene* **280**, 37-48 (2001).
470. Dugas, B. *et al.* Activation and infection of B cells by Epstein-Barr virus. Role of calcium mobilization and of protein kinase C translocation. *J Immunol* **141**, 4344-51 (1988).
471. Dugas, B., Mencia-Huerta, J.M., Braquet, P., Galanaud, P. & Delfraissy, J.F. Extracellular but not intracellular calcium mobilization is required for Epstein-Barr virus-containing supernatant-induced B cell activation. *Eur J Immunol* **19**, 1867-71 (1989).
472. Curtis, D. *et al.* Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes. *Psychiatr Genet* **21**, 1-4 (2011).
473. Jia, X. *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS one* **8**, e64683 (2013).
474. de Sanjose, S. *et al.* Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. *The Journal of infectious diseases* **199**, 1449-56 (2009).
475. Guttman-Yassky, E. *et al.* Familial clustering of classic Kaposi sarcoma. *J Infect Dis* **189**, 2023-6 (2004).
476. Kaasinen, E. *et al.* Nationwide registry-based analysis of cancer clustering detects strong familial occurrence of Kaposi sarcoma. *PLoS One* **8**, e55209 (2013).
477. Jackson, C.C. *et al.* Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. *Pediatr Blood Cancer* **63**, 392-7 (2016).
478. Camcioglu, Y. *et al.* HHV-8-associated Kaposi sarcoma in a child with IFN γ R1 deficiency. *J Pediatr* **144**, 519-23 (2004).
479. Picard, C. *et al.* Kaposi's sarcoma in a child with Wiskott-Aldrich syndrome. *Eur J Pediatr* **165**, 453-7 (2006).
480. Sahin, G. *et al.* Classic Kaposi Sarcoma in 3 Unrelated Turkish Children Born to Consanguineous Kindreds. *Pediatrics* **125**, e704-e708 (2010).
481. Byun, M. *et al.* Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. *J Exp Med* **207**, 2307-12 (2010).
482. Byun, M. *et al.* Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. *J Exp Med* **210**, 1743-59 (2013).

483. Pedergnana, V. *et al.* A major locus on chromosome 3p22 conferring predisposition to human herpesvirus 8 infection. *Eur J Hum Genet* **20**, 690-5 (2012).
484. Plancoulaine, S., Gessain, A., van Beveren, M., Tortevoeye, P. & Abel, L. Evidence for a recessive major gene predisposing to human herpesvirus 8 (HHV-8) infection in a population in which HHV-8 is endemic. *J Infect Dis* **187**, 1944-50 (2003).
485. Alcais, A. *et al.* Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? *Ann N Y Acad Sci* **1214**, 18-33 (2010).
486. Delves, P.J. & Roitt, I.M. The immune system. Second of two parts. *N Engl J Med* **343**, 108-17 (2000).
487. Chang, J., Renne, R., Dittmer, D. & Ganem, D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. *Virology* **266**, 17-25 (2000).
488. Ensoli, B., Barillari, G. & Gallo, R.C. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Immunol Rev* **127**, 147-55 (1992).
489. Brulois, K. & Jung, J.U. Interplay between Kaposi's sarcoma-associated herpesvirus and the innate immune system. *Cytokine Growth Factor Rev* **25**, 597-609 (2014).
490. Coscoy, L. Immune evasion by Kaposi's sarcoma-associated herpesvirus. *Nat Rev Immunol* **7**, 391-401 (2007).
491. Lehrnbecher, T.L. *et al.* Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. *Blood* **95**, 2386-90 (2000).
492. Brown, E.E. *et al.* A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. *Cancer Epidemiol Biomarkers Prev* **14**, 633-7 (2005).
493. Foster, C.B. *et al.* An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. *Blood* **96**, 2562-7 (2000).
494. Fishman, D. *et al.* The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J Clin Invest* **102**, 1369-76 (1998).
495. van der Kuyl, A.C. *et al.* An IL-8 gene promoter polymorphism is associated with the risk of the development of AIDS-related Kaposi's sarcoma: a case-control study. *AIDS* **18**, 1206-8 (2004).
496. Lane, B.R. *et al.* Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma. *J Virol* **76**, 11570-83 (2002).
497. Masood, R. *et al.* Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma. *Clin Cancer Res* **7**, 2693-702 (2001).
498. Matsumoto, T. *et al.* Elevated serum levels of IL-8 in patients with HIV infection. *Clin Exp Immunol* **93**, 149-51 (1993).
499. Brown, E.E. *et al.* Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. *Cancer Epidemiol Biomarkers Prev* **15**, 926-34 (2006).

500. Brown, E.E. *et al.* Host immunogenetics and control of human herpesvirus-8 infection. *J Infect Dis* **193**, 1054-62 (2006).
501. Brunson, M.E., Balakrishnan, K. & Penn, I. HLA and Kaposi's sarcoma in solid organ transplantation. *Hum Immunol* **29**, 56-63 (1990).
502. Contu, L. & Cerimele, P. HLA and classic Kaposi's sarcoma in Sardinia. *J Am Acad Dermatol* **30**, 508-9 (1994).
503. Crosslin, D.R. *et al.* Genetic variation in the HLA region is associated with susceptibility to herpes zoster. *Genes Immun* **16**, 1-7 (2015).
504. Delahaye-Sourdeix, M. *et al.* A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma. *Cancer Epidemiol Biomarkers Prev* **24**, 1838-43 (2015).
505. Fitzmaurice, K. *et al.* Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. *Gut* **64**, 813-9 (2015).
506. McLaren, P.J. & Carrington, M. The impact of host genetic variation on infection with HIV-1. *Nature immunology* **16**, 577-83 (2015).
507. Tekola Ayele, F. *et al.* HLA class II locus and susceptibility to podoconiosis. *N Engl J Med* **366**, 1200-8 (2012).
508. Melbye, M., Kestens, L., Biggar, R.J., Schreuder, G.M. & Gigase, P.L. HLA studies of endemic African Kaposi's sarcoma patients and matched controls: no association with HLA-DR5. *Int J Cancer* **39**, 182-4 (1987).
509. Robbins, E., Cohen, N., Contu, L. & Dausset, J. A study of the HLA-D region in patients with classic Kaposi's sarcoma. *Immunogenetics* **24**, 115-7 (1986).
510. Papasteriades, C. *et al.* Histocompatibility antigens HLA-A, -B, -DR in Greek patients with Kaposi's sarcoma. *Tissue Antigens* **24**, 313-5 (1984).
511. Contu, L., Cerimele, D., Pintus, A., Cottoni, F. & La Nasa, G. HLA and Kaposi's sarcoma in Sardinia. *Tissue Antigens* **23**, 240-5 (1984).
512. Pollack, M.S. *et al.* Frequencies of HLA and Gm immunogenetic markers in Kaposi's sarcoma. *Tissue Antigens* **21**, 1-8 (1983).
513. Ohara, N. & Chang, S.W. Kaposi's sarcoma and the HLA-Dr5 alloantigen. *Ann Intern Med* **97**, 617 (1982).
514. Ioannidis, J.P., Skolnik, P.R., Chalmers, T.C. & Lau, J. Human leukocyte antigen associations of epidemic Kaposi's sarcoma. *AIDS* **9**, 649-51 (1995).
515. Masala, M.V. *et al.* Classic Kaposi's sarcoma in Sardinia: HLA positive and negative associations. *Int J Dermatol* **44**, 743-5 (2005).
516. Dorak, M.T. *et al.* HLA-B, -DRB1/3/4/5, and -DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. *Journal of medical virology* **76**, 302-10 (2005).
517. Guerini, F.R. *et al.* Association of HLA-DRB1 and -DQB1 with Classic Kaposi's Sarcoma in Mainland Italy. *Cancer Genomics Proteomics* **3**, 191-196 (2006).
518. Aissani, B. *et al.* SNP screening of central MHC-identified HLA-DMB as a candidate susceptibility gene for HIV-related Kaposi's sarcoma. *Genes and immunity* **15**, 424-9 (2014).

519. Goedert, J.J. *et al.* Risk of Classic Kaposi Sarcoma With Combinations of Killer Immunoglobulin-Like Receptor and Human Leukocyte Antigen Loci: A Population-Based Case-control Study. *The Journal of infectious diseases* **213**, 432-8 (2016).
520. Aavikko, M. *et al.* Whole-Genome Sequencing Identifies STAT4 as a Putative Susceptibility Gene in Classic Kaposi Sarcoma. *J Infect Dis* **211**, 1842-51 (2015).
521. Takeda, K. & Akira, S. STAT family of transcription factors in cytokine-mediated biological responses. *Cytokine Growth Factor Rev* **11**, 199-207 (2000).
522. Zhang, F. & Boothby, M. T helper type 1-specific Brg1 recruitment and remodeling of nucleosomes positioned at the IFN-gamma promoter are Stat4 dependent. *J Exp Med* **203**, 1493-505 (2006).
523. Yang, D. *et al.* Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. *Proceedings of the National Academy of Sciences of the United States of America* **111**, E4762-8 (2014).
524. Gregory, S.M. *et al.* Toll-like receptor signaling controls reactivation of KSHV from latency. *Proc Natl Acad Sci U S A* **106**, 11725-30 (2009).
525. Cannon, M.J. *et al.* Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. *AIDS* **17**, 215-22 (2003).
526. Butler, L.M. *et al.* Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3. *J Virol* **86**, 7158-66 (2012).
527. Sabbah, S. *et al.* T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. *Blood* **119**, 2083-92 (2012).
528. Thakker, S. *et al.* Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex. *J Virol* **89**, 5536-56 (2015).
529. Coit, P. *et al.* Ethnicity-specific epigenetic variation in naive CD4+ T cells and the susceptibility to autoimmunity. *Epigenetics Chromatin* **8**, 49 (2015).
530. Campbell, M., Kung, H.J. & Izumiya, Y. Long non-coding RNA and epigenetic gene regulation of KSHV. *Viruses* **6**, 4165-77 (2014).
531. Heward, J.A. & Lindsay, M.A. Long non-coding RNAs in the regulation of the immune response. *Trends Immunol* **35**, 408-19 (2014).
532. Rice, G.I. *et al.* Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. *Nat Genet* **41**, 829-32 (2009).
533. Laguette, N. *et al.* SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature* **474**, 654-7 (2011).
534. Lahouassa, H. *et al.* SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. *Nat Immunol* **13**, 223-8 (2012).

535. Descours, B. *et al.* SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. *Retrovirology* **9**, 87 (2012).
536. Bhattacharya, M.R. *et al.* TMEM184b Promotes Axon Degeneration and Neuromuscular Junction Maintenance. *J Neurosci* **36**, 4681-9 (2016).
537. Latourelle, J.C., Dumitriu, A., Hadzi, T.C., Beach, T.G. & Myers, R.H. Evaluation of Parkinson disease risk variants as expression-QTLs. *PLoS One* **7**, e46199 (2012).
538. Grozeva, D. *et al.* Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability. *Hum Mutat* **36**, 1197-204 (2015).
539. Halgren, C. *et al.* Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. *Clin Genet* **82**, 248-55 (2012).
540. Hoyer, J. *et al.* Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. *Am J Hum Genet* **90**, 565-72 (2012).
541. Margolskee, E. *et al.* Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. *Oncotarget* (2016).
542. Schatz, J.H. *et al.* Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. *Leukemia* **29**, 237-41 (2015).
543. Fujimoto, A. *et al.* Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nat Genet* **44**, 760-4 (2012).
544. Lieberman, P.M. Keeping it quiet: chromatin control of gammaherpesvirus latency. *Nat Rev Microbiol* **11**, 863-75 (2013).
545. Lu, F. *et al.* Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. *J Virol* **77**, 11425-35 (2003).
546. Mercier, A., Arias, C., Madrid, A.S., Holdorf, M.M. & Ganem, D. Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation. *J Virol* **88**, 6762-77 (2014).
547. Van den Broeke, C. & Favoreel, H.W. Actin' up: herpesvirus interactions with Rho GTPase signaling. *Viruses* **3**, 278-92 (2011).
548. Van den Broeke, C., Jacob, T. & Favoreel, H.W. Rho'ing in and out of cells: viral interactions with Rho GTPase signaling. *Small GTPases* **5**, e28318 (2014).
549. Montaner, S. *et al.* The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. *Blood* **104**, 2903-11 (2004).
550. Veettil, M.V. *et al.* RhoA-GTPase facilitates entry of Kaposi's sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner. *J Virol* **80**, 11432-46 (2006).
551. Schulz, T.F. KSHV/HHV8-associated lymphoproliferations in the AIDS setting. *Eur J Cancer* **37**, 1217-26 (2001).

552. Bolormaa, S., Pryce, J.E., Hayes, B.J. & Goddard, M.E. Multivariate analysis of a genome-wide association study in dairy cattle. *J Dairy Sci* **93**, 3818-33 (2010).
553. Zheng, H. *et al.* The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-kappaB activation by dephosphorylating the protein kinase TAK1. *J Biol Chem* **288**, 819-25 (2013).
554. Keller, S.A. *et al.* NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. *Blood* **107**, 3295-302 (2006).
555. Grossmann, C. & Ganem, D. Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. *Virology* **375**, 94-102 (2008).
556. Lippert, D.N. & Wilkins, J.A. Glia maturation factor gamma regulates the migration and adherence of human T lymphocytes. *BMC Immunol* **13**, 21 (2012).
557. Zuo, P. *et al.* High GMFG expression correlates with poor prognosis and promotes cell migration and invasion in epithelial ovarian cancer. *Gynecol Oncol* **132**, 745-51 (2014).
558. Mbisa, G.L. *et al.* Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. *J Immunol Methods* **356**, 39-46 (2010).
559. Neipel, F., Albrecht, J.C. & Fleckenstein, B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? *J Virol* **71**, 4187-92 (1997).
560. Rezaee, S.A., Cunningham, C., Davison, A.J. & Blackbourn, D.J. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. *J Gen Virol* **87**, 1781-804 (2006).
561. Brulois, K.F. *et al.* Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. *J Virol* **86**, 9708-20 (2012).
562. Yakushko, Y. *et al.* Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome contains a duplication of a long unique-region fragment within the terminal repeat region. *J Virol* **85**, 4612-7 (2011).
563. Tamburro, K.M. *et al.* Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. *Virology* **433**, 220-5 (2012).
564. Olp, L.N., Jeanniard, A., Marimo, C., West, J.T. & Wood, C. Whole-Genome Sequencing of Kaposi's Sarcoma-Associated Herpesvirus from Zambian Kaposi's Sarcoma Biopsy Specimens Reveals Unique Viral Diversity. *J Virol* **89**, 12299-308 (2015).
565. Dresang, L.R. *et al.* Coupled transcriptome and proteome analysis of human lymphotropic tumor viruses: insights on the detection and discovery of viral genes. *BMC Genomics* **12**, 625 (2011).
566. Arias, C. *et al.* KSHV 2.0: A Comprehensive Annotation of the Kaposi's Sarcoma-Associated Herpesvirus Genome Using Next-Generation Sequencing Reveals Novel Genomic and Functional Features. *PLoS Pathog* **10**, e1003847 (2014).

567. Meng, Y.X. *et al.* Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. *Virology* **261**, 106-19 (1999).
568. Lacoste, V. *et al.* Molecular characterization of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 strains from Russia. *J Gen Virol* **81**, 1217-22 (2000).
569. Poole, L.J. *et al.* Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. *J Virol* **73**, 6646-60 (1999).
570. Lacoste, V. *et al.* Molecular epidemiology of human herpesvirus 8 in africa: both B and A5 K1 genotypes, as well as the M and P genotypes of K14.1/K15 loci, are frequent and widespread. *Virology* **278**, 60-74 (2000).
571. Tornesello, M.L. *et al.* Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. *Virology* **398**, 280-9 (2010).
572. Diamond, J. & Bellwood, P. Farmers and their languages: the first expansions. *Science* **300**, 597-603 (2003).
573. Salas, A. *et al.* The making of the African mtDNA landscape. *Am J Hum Genet* **71**, 1082-111 (2002).
574. Simpson, G.R. *et al.* Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. *Lancet* **348**, 1133-8 (1996).
575. Kakoola, D.N. *et al.* Recombination in human herpesvirus-8 strains from Uganda and evolution of the K15 gene. *J Gen Virol* **82**, 2393-404 (2001).
576. Kajumbula, H. *et al.* Ugandan Kaposi's sarcoma-associated herpesvirus phylogeny: evidence for cross-ethnic transmission of viral subtypes. *Intervirol* **49**, 133-43 (2006).
577. Lallemand, F., Desire, N., Rozenbaum, W., Nicolas, J.-c. & Marechal, V. Quantitative Analysis of Human Herpesvirus 8 Viral Load Using a Real-Time PCR Assay. **38**, 1404-1408 (2000).
578. Pardieu, C. *et al.* The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. *PLoS pathogens* **6**, e1000843 (2010).
579. Watson, S.J. *et al.* Viral population analysis and minority-variant detection using short read next-generation sequencing. *Philos Trans R Soc Lond B Biol Sci* **368**, 20120205 (2013).
580. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754-60 (2009).
581. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-9 (2009).
582. Katoh, K. & Standley, D.M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* **30**, 772-80 (2013).

583. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* **30**, 1312-3 (2014).
584. Depledge, D.P. *et al.* Specific capture and whole-genome sequencing of viruses from clinical samples. *PLoS One* **6**, e27805 (2011).
585. Brayfield, B.P. *et al.* Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission. *J Infect Dis* **189**, 2260-70 (2004).
586. Palser, A.L. *et al.* Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. *J Virol* **89**, 5222-37 (2015).
587. Pauk, J. *et al.* Mucosal shedding of human herpesvirus 8 in men. *N Engl J Med* **343**, 1369-77 (2000).
588. Taylor, M.M. *et al.* Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. *J Infect Dis* **190**, 484-8 (2004).
589. Corey, L., Brodie, S., Huang, M.L., Koelle, D.M. & Wald, A. HHV-8 infection: a model for reactivation and transmission. *Rev Med Virol* **12**, 47-63 (2002).
590. Bender Ignacio, R.A. *et al.* Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. *Infect Agent Cancer* **11**, 7 (2016).
591. Stebbing, J. *et al.* Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. *J Virol* **77**, 4306-14 (2003).
592. Greenspan, G. *et al.* Model-based inference of recombination hotspots in a highly variable oncogene [corrected]. *J Mol Evol* **58**, 239-51 (2004).
593. Boshoff, C. & Weiss, R.A. Kaposi's sarcoma-associated herpesvirus. *Adv Cancer Res* **75**, 57-86 (1998).
594. Kwok, H. *et al.* Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. *J Virol* **88**, 10662-72 (2014).
595. Cassar, O. *et al.* Divergent KSHV/HHV-8 subtype D strains in New Caledonia and Solomon Islands, Melanesia. *J Clin Virol* **53**, 214-8 (2012).
596. Kasolo, F.C., Spinks, J., Bima, H., Bates, M. & Gompels, U.A. Diverse genotypes of Kaposi's sarcoma associated herpesvirus (KSHV) identified in infant blood infections in African childhood-KS and HIV/AIDS endemic region. *J Med Virol* **79**, 1555-61 (2007).
597. Ramos da Silva, S., Ferraz da Silva, A.P., Bacchi, M.M., Bacchi, C.E. & Elgui de Oliveira, D. KSHV genotypes A and C are more frequent in Kaposi sarcoma lesions from Brazilian patients with and without HIV infection, respectively. *Cancer Lett* **301**, 85-94 (2011).
598. Zhang, Y. *et al.* Distinct distribution of rare us kshv genotypes in south texas. Implications for kshv epidemiology and evolution. *Ann Epidemiol* **10**, 470 (2000).
599. Kouri, V. *et al.* Kaposi's Sarcoma and Human Herpesvirus 8 in Cuba: evidence of subtype B expansion. *Virology* **432**, 361-9 (2012).
600. Ouyang, X. *et al.* Genotypic analysis of Kaposi's sarcoma-associated herpesvirus from patients with Kaposi's sarcoma in Xinjiang, China. *Viruses* **6**, 4800-10 (2014).

601. Jalilvand, S. *et al.* Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. *Virus Res* **163**, 644-9 (2012).
602. Betsem, E. *et al.* Epidemiology and genetic variability of HHV-8/KSHV in Pygmy and Bantu populations in Cameroon. *PLoS Negl Trop Dis* **8**, e2851 (2014).
603. Whitby, D. *et al.* Genotypic characterization of Kaposi's sarcoma-associated herpesvirus in asymptomatic infected subjects from isolated populations. *J Gen Virol* **85**, 155-63 (2004).
604. Isaacs, T., Abera, A.B., Muloiwa, R., Katz, A.A. & Todd, G. Genetic diversity of HHV8 subtypes in South Africa: A5 subtype is associated with extensive disease in AIDS-KS. *J Med Virol* **88**, 292-303 (2016).
605. Bourboulia, D. *et al.* Serologic evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus infection. *JAMA* **280**, 31-2 (1998).
606. Frayling, T.M. *et al.* A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**, 889-94 (2007).
607. Gerken, T. *et al.* The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. *Science* **318**, 1469-72 (2007).
608. Herman, M.A. & Rosen, E.D. Making Biological Sense of GWAS Data: Lessons from the FTO Locus. *Cell Metab* **22**, 538-9 (2015).
609. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. *N Engl J Med* **373**, 895-907 (2015).
610. Lee, S., Abecasis, G.R., Boehnke, M. & Lin, X. Rare-variant association analysis: study designs and statistical tests. *Am J Hum Genet* **95**, 5-23 (2014).
611. Zuk, O. *et al.* Searching for missing heritability: designing rare variant association studies. *Proc Natl Acad Sci U S A* **111**, E455-64 (2014).
612. Bartha, I. *et al.* A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. *Elife* **2**, e01123 (2013).